CD8A and hepatocellular carcinoma: As expected, a combinational analysis of CD3 (e.g. CD3CTHi CD3IMHi vs. CD3CTLo CD3IMLo) efficiently predicted the HCC survival even within same TNM-I stage (Figure 4E) or BLCL-B stage (Figure 4F) patients, which might be repeated by a combinational analysis of location and density of CD8+ T cells [7-8].